Policy & Regulation
Leqembi approved in Hong Kong
11 July 2024 -

Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its partner Eisai Co Ltd (TYO:4523) announced on Thursday that Hong Kong has approved Leqembi (lecanemab) for Alzheimer's disease.

The treatment is for patients with mild cognitive impairment or mild dementia.

Hong Kong joins the United States, Japan, China and South Korea in approving the drug.

Developed by BioArctic and Eisai, Leqembi reduces amyloid-beta plaques in the brain and slows cognitive decline. Eisai has submitted applications for approval in 13 other countries and regions.

Login
Username:

Password: